"The development of RBP-6000 further builds on Indivior's commitment to expand and strengthen our addiction portfolio, most recently demonstrated with Suboxone® Film which has achieved a 61% share of the U.S. market as of 30 June 2016 ," Shaun Thaxter continued. "This market leadership is testament to Indivior's ability to leverage the insights and experience of opinion leaders, healthcare professionals, patients and other stakeholders in developing innovative medical treatments for opioid use disorder."